High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer results of comprehensive re-evaluation of multi-institutional case series /
Oestrogen receptor (ER)-negative (-) progesterone receptor (PgR)-positive (+) is the least common combination of steroid receptor expression observed in breast cancer. There are many controversies regarding the actual existence of ER-/PgR+ phenotype. In the current study, we aimed to perform compreh...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | PATHOLOGY
54 No. 3 |
| Tárgyszavak: | |
| doi: | 10.1016/j.pathol.2021.10.003 |
| mtmt: | 33178139 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/29625 |
| LEADER | 03135nab a2200373 i 4500 | ||
|---|---|---|---|
| 001 | publ29625 | ||
| 005 | 20240221080751.0 | ||
| 008 | 240221s2022 hu o 0|| eng d | ||
| 022 | |a 0031-3025 | ||
| 024 | 7 | |a 10.1016/j.pathol.2021.10.003 |2 doi | |
| 024 | 7 | |a 33178139 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kunc Michal | |
| 245 | 1 | 0 | |a High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer |h [elektronikus dokumentum] : |b results of comprehensive re-evaluation of multi-institutional case series / |c Kunc Michal |
| 260 | |c 2022 | ||
| 300 | |a 269-278 | ||
| 490 | 0 | |a PATHOLOGY |v 54 No. 3 | |
| 520 | 3 | |a Oestrogen receptor (ER)-negative (-) progesterone receptor (PgR)-positive (+) is the least common combination of steroid receptor expression observed in breast cancer. There are many controversies regarding the actual existence of ER-/PgR+ phenotype. In the current study, we aimed to perform comprehensive immunohistochemical re-evaluation of ER-/PgR+ breast cancers from multiple institutions. A total of 135 cases of ER-/PgR+ breast cancer were collected from 11 institutions from the period 2006-2020 and subsequently stained with three clinically validated anti-ER antibody clones: SP1 (Roche), 1D5 (Dako), and EP1 (Dako), and two anti-PgR antibody clones: 636 (Dako), and 1E2 (Roche). Clinicopathological characteristics of confirmed and re-categorised cases were analysed. Seventy-six cases retained the original ER-/ PgR+ phenotype, including 21 HER2+ and 55 HER2- tumours. Forty-seven cases were ER+ with at least one anti ER antibody, and 12 cases were re-categorised as double negatives across all anti-ER and anti-PgR antibodies. No significant differences in survival were observed between groups in the HER2+ category. In the HER2- cohort, confirmed ER-/PgR+, ER+ tumours with discrepant ER staining, and triple negatives had inferior overall survival compared to concordant ER+ cases. Progesterone receptor expression in >20% of cells was identified as an adverse prognostic factor in ER-/PgR+/HER2- breast cancer in a multivariable model adjusted by stage (HR 5.0, 95% CI 1.3-19.2, p=0.019). We performed one of the largest validation studies so far on ER-/PgR+ breast cancer and confirmed the existence of this subgroup. Moreover, we identified high PgR expression as an adverse prognostic factor. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Peksa Rafal |e aut |
| 700 | 0 | 1 | |a Cserni Gábor |e aut |
| 700 | 0 | 2 | |a Izycka-Swieszewska Ewa |e aut |
| 700 | 0 | 2 | |a Lacko Aleksandra |e aut |
| 700 | 0 | 2 | |a Radecka Barbara |e aut |
| 700 | 0 | 2 | |a Braun Marcin |e aut |
| 700 | 0 | 2 | |a Pikiel Joanna |e aut |
| 700 | 0 | 2 | |a Litwiniuk Maria |e aut |
| 700 | 0 | 2 | |a Pogoda Katarzyna |e aut |
| 700 | 0 | 2 | |a Szwajkosz Anna |e aut |
| 700 | 0 | 2 | |a Biernat Wojciech |e aut |
| 700 | 0 | 2 | |a Senkus Elzbieta |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/29625/3/33178139_megjelent.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/29625/1/Pathology_clean-SZTERepositorium.pdf |z Dokumentum-elérés |